Castleman disease was initially described as a lymphoproliferative disorder causing mediastinal masses characterized by abnormal histopathology. 1 Castleman disease has since been subclassified clinically into unicentric (UCD) and multicentric Castleman disease (MCD), 2 and subclassified histopathologically into the hyaline-vascular type (HV), plasma-cell type (PC), mixed type, plasmablastic type, and hypervascular type. 3 MCD was recently subclassified into human herpes virus-8 (HHV-8)-associated, HHV-8unassociated (idiopathic MCD [iMCD]), POEMS syndromeassociated, and others. 3 A new clinical entity, TAFRO syndrome, characterized by thrombocytopenia, anasarca (edema, pleural effusion, and ascites), fever, reticulin myelofibrosis (or renal insufficiency), and organomegaly (hepatosplenomegaly and lymphadenopathy), was recently described. 4 Its diagnostic criteria and disease severity criteria, determined by the All Japan TAFRO Syndrome Research Group in the Research Program for Intractable Diseases of the Ministry of Health, Labour and Welfare (MHLW) of Japan, 5 were recently updated (https:// www.facebook.com/CastlemanTAFRO). As the lymph nodes of individuals with TAFRO syndrome were characterized histopathologically as Castleman disease, 6 TAFRO syndrome has been categorized as part of iMCD. Recently, clinical and basic studies on Castleman disease and TAFRO syndrome were started in Japan and the USA. We collected and analyzed data from more than 200 patients with iMCD, TAFRO syndrome, or conditions mimicking these disorders. Most patients with iMCD exhibit a chronic/ indolent clinical course, characterized by polyclonal hypergammopathy, multiple lymphadenopathy, and thrombocytosis. In contrast, most patients with TAFRO syndrome have an acute or sub-acute onset and progressive clinical course, characterized by normal to reduced gammaglobulin levels, thrombocytopenia, small or unnoticeable lymph nodes, and severe pleural effusion, ascites, and anasarca. Lymph node